Literature DB >> 18684792

Quality of life and inflammation in exacerbations of bronchiectasis.

J M Courtney1, M G Kelly, A Watt, L Garske, J Bradley, M Ennis, J S Elborn.   

Abstract

Patients with bronchiectasis often have impaired quality of life (QoL), which deteriorates with exacerbations. The aim of this study was to investigate changes in QoL and how these were influenced by changes in airway physiology and inflammation in patients with bronchiectasis before and after resolution of an exacerbation. Sputum induction and a QoL questionnaire were undertaken on the first day, day 14, and 4 weeks after completion of intravenous antibiotics (day 42). Eighteen patients (12 female) were recruited, median (IQ range) age of 54 (47-60) years. There was a trend towards an improvement in lung function from visit 1 to visit 2, but this was not statistically significant. C-reactive protein (CRP) [mean (SEM)] reduced between visit 1 and visit 2 [55.4 (21.5) vs 9.4 (3.1) mg/L, P = 0.03] but did not increase significantly on visit 3 [44.4 (32.9) mg/L, P = 0.27]. The median (interquartile range) sputum cell count (x10(6) cells/g of sputum) decreased from visit 1 to visit 2 [21.6 (11.8-37.6)-13.3 (6.7-22.9) x 10(6) cells/g, respectively, P = 0.008] and increased from visit 2 to visit 3 [26.3 (14.1-33.6) x 10(6) cells/g, P = 0.03]. All soluble markers of inflammation significantly reduced from visit 1 to visit 2 but increased on visit 3 with the exception of TNF-alpha. Regarding QoL, three of the four domains (dyspnoea, emotional, mastery) significantly improved from visit 1 to visit 2 but did not change between visit 2 and visit 3. The improvements in QoL scores could not be explained by the improvements in lung function or inflammatory markers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18684792     DOI: 10.1177/1479972308091823

Source DB:  PubMed          Journal:  Chron Respir Dis        ISSN: 1479-9723            Impact factor:   2.444


  12 in total

Review 1.  [Treatment of not-with cystic fibrosis associated forms bronchiectasis (non-CF bronchiectasis)].

Authors:  J Rademacher; M W Pletz; T Welte
Journal:  Internist (Berl)       Date:  2010-12       Impact factor: 0.743

2.  Could vitamin d have a potential anti-inflammatory and anti-infective role in bronchiectasis?

Authors:  Jim Bartley; Jeff Garrett; Cameron C Grant; Carlos A Camargo
Journal:  Curr Infect Dis Rep       Date:  2013-04       Impact factor: 3.725

3.  Quality of life in patients with bronchiectasis: a 2-year longitudinal study.

Authors:  Anil Magge; Shehryar Ashraf; Alexandra L Quittner; Mark L Metersky
Journal:  Ann Transl Med       Date:  2019-07

4.  Serum albumin is a predictor of respiratory hospitalization in patients with bronchiectasis.

Authors:  Sunmi Ju; Jong Hwan Jeong; Manbong Heo; I Re Heo; Tae Hoon Kim; Ho Cheol Kim; Jung-Wan Yoo; Yu Ji Cho; Yi Yeong Jeong; Jong Deog Lee; Seung Jun Lee
Journal:  Chron Respir Dis       Date:  2021 Jan-Dec       Impact factor: 2.444

5.  Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial.

Authors:  Anne B Chang; Keith Grimwood; Colin F Robertson; Andrew C Wilson; Peter P van Asperen; Kerry-Ann F O'Grady; Theo P Sloots; Paul J Torzillo; Emily J Bailey; Gabrielle B McCallum; Ian B Masters; Catherine A Byrnes; Mark D Chatfield; Helen M Buntain; Ian M Mackay; Peter S Morris
Journal:  Trials       Date:  2012-08-31       Impact factor: 2.279

6.  Exploring the associations between systemic inflammation, obesity and healthy days: a health related quality of life (HRQOL) analysis of NHANES 2005-2008.

Authors:  Jeffrey Wilkins; Palash Ghosh; Juan Vivar; Bibhas Chakraborty; Sujoy Ghosh
Journal:  BMC Obes       Date:  2018-08-06

7.  Diagnosing and preventing chronic suppurative lung disease (CSLD) and bronchiectasis.

Authors:  A B Chang; C A Byrnes; M L Everard
Journal:  Paediatr Respir Rev       Date:  2010-12-04       Impact factor: 2.726

8.  Extrapulmonary features of bronchiectasis: muscle function, exercise capacity, fatigue, and health status.

Authors:  Ozge Ozalp; Deniz Inal-Ince; Ebru Calik; Naciye Vardar-Yagli; Melda Saglam; Sema Savci; Hulya Arikan; Meral Bosnak-Guclu; Lutfi Coplu
Journal:  Multidiscip Respir Med       Date:  2012-06-11

9.  Bronchiectasis exacerbation study on azithromycin and amoxycillin-clavulanate for respiratory exacerbations in children (BEST-2): study protocol for a randomized controlled trial.

Authors:  Anne B Chang; Keith Grimwood; Andrew C Wilson; Peter P van Asperen; Catherine A Byrnes; Kerry-Ann F O'Grady; Theo P Sloots; Colin F Robertson; Paul J Torzillo; Gabrielle B McCallum; Ian B Masters; Helen M Buntain; Ian M Mackay; Jacobus Ungerer; Joanne Tuppin; Peter S Morris
Journal:  Trials       Date:  2013-02-20       Impact factor: 2.279

Review 10.  Inhaled non-steroid anti-inflammatories for children and adults with bronchiectasis.

Authors:  Susan J Pizzutto; John W Upham; Stephanie T Yerkovich; Anne B Chang
Journal:  Cochrane Database Syst Rev       Date:  2016-01-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.